titoli, abstracts, parole chiave >>>
Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma

Venturini, Marco and Durando, Antonio and Garrone, Ornella and Colozza, Maria Antonietta and Contu, Antonio Silverio and Stevani, Ilaria and Genta, Franco and Bighin, Claudia and Lambiase, Antonio and Del Mastro, Lucia (2003) Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma. Cancer, Vol. 97 (5), p. 1174-1180. eISSN 1097-0142. Article.

Full text not available from this repository.

DOI: 10.1002/cncr.11203

Abstract

BACKGROUND. The objective of this study was to evaluate the activity and safety of oral capecitabine in combination with docetaxel and epirubicin (TEX) as first-line treatment for patients with locally advanced/metastatic breast carcinoma. METHODS. This open-label, Phase II study was conducted at six Italian centers. Treatment consisted of epirubicin, 75 mg/m2 (intravenous bolus), and docetaxel, 75 mg/ m2 (1-hour infusion), both administered on Day 1, plus oral capecitabine, 1000 mg/ m2 twice daily, on Days 1–14 of each 3-week treatment cycle. RESULTS. A total of 67 patients received 392 cycles of treatment, with a median of 6 cycles in patients with Stage III disease (n = 34 patients) and a median of 8 cycles in patients with Stage IV disease (n = 33 patients). The objective response rate was 82%, including complete responses in 21% of patients. A greater proportion of patients with Stage III disease achieved tumor responses compared with patients who had Stage IV disease (97% vs. 67%, respectively). Among 34 patients with Stage III disease, pathologic complete responses were confirmed in 10 patients (29%). TEX chemotherapy demonstrated an acceptable safety profile. There was a low incidence of Grade 3 adverse events, and Grade 4 adverse events were particularly rare (4%). The most common Grade 3–4 adverse event was febrile neutropenia, which occurred in 16% of patients. CONCLUSIONS. TEX combination therapy has important antitumor activity and an acceptable safety profile in this setting. A large, randomized, Phase III trial is ongoing to compare TEX chemotherapy with an epirubicin plus docetaxel regimen in patients with untreated, advanced breast carcinoma.

Item Type:Article
ID Code:1335
Status:Published
Refereed:Yes
Uncontrolled Keywords:Advanced breast carcinoma, Phase II, capecitabine, docetaxel, epirubicin
Subjects:Area 06 - Scienze mediche > MED/42 Igiene generale e applicata
Divisions:002 Altri enti e centri di ricerca del Nord Sardegna > Azienda ASL1, Sassari > Ospedale civile SS. Annunziata > Ambulatorio oncologia medica
Publisher:Wiley
eISSN:1097-0142
Copyright Holders:© 2003 American Cancer Society
Deposited On:18 Aug 2009 10:04

I documenti depositati in UnissResearch sono protetti dalle leggi che regolano il diritto d'autore

Repository Staff Only: item control page